Selected Quarterly Financial Information (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended																	12 Months Ended
	Dec. 31, 2018	[1]	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2017	[2]	Sep. 30, 2017	[2]	Jun. 30, 2017	[2]	Mar. 31, 2017	[2]	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2018		Dec. 31, 2017		Dec. 31, 2016
Selected Quarterly Financial Information [Abstract]
REVENUE	$ 67,799		$ 64,598	$ 68,496	$ 61,948	$ 52,826		$ 43,999		$ 47,818		$ 45,059		$ 45,029	$ 45,252	$ 47,083	$ 43,016	$ 262,841		$ 189,702		$ 180,380
GROSS MARGIN	45,191		42,714	45,851	39,228	36,363		29,862		32,905		29,512		31,195	29,782	30,301	27,621	172,984		128,642		118,899
NET INCOME (LOSS)	$ (776)		$ 1,565	$ 226	$ (3,855)	$ (3,007)		$ 1,325		$ 3,163		$ 2,223		$ 2,897	$ 2,993	$ 2,347	$ 2,541	$ (2,840)		$ 3,704		$ 10,778
INCOME (LOSS) PER COMMON SHARE - DILUTED	$ (0.02)		$ 0.04	$ 0.01	$ (0.11)	$ 0.09		$ 0.04		$ 0.09		$ 0.06		$ 0.09	$ 0.09	$ 0.07	$ 0.08	$ (0.08)	[3]	$ 0.11	[3]	$ 0.32	[3]

[1] In December 2017 we completed our acquisition of JOTEC, which is also being operated as a wholly-owned subsidiary of CryoLife.

[2] In January 2016 we completed our acquisition of On-X Life Technologies Holdings, Inc., which is being operated as a wholly-owned subsidiary of CryoLife. In 2016 we also sold our HeRO Graft product line and our ProCol product line, and ceased sales of these products during 2016.

[3] We excluded stock options from the calculation of diluted weighted-average common shares outstanding if the per share value, including the sum of (i) the exercise price of the options and (ii) the amount of the compensation cost attributed to future services and not yet recognized, was greater than the average market price of the shares, because the inclusion of these stock options would be antidilutive to (loss) income per common share. For the year ended December 31, 2018 all stock options and awards were excluded from the calculation of weighted-average common shares outstanding as these would be antidilutive to the net loss. For the years ended December 31, 2017 and 2016 stock options to purchase 227,000 and 1,000 shares, respectively, were excluded from the calculation of diluted weighted-average common shares outstanding.